Akari Therapeutics plc ADR (0.01 USD)
Symbol: AKTX (NASDAQ)
0.79
▲ (3.12%) 0.024
Company Description:
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Key Stats
- Today's Open: $0.77
- Today's High: $0.805
- Today's Low: $0.754
- Today's Volume: 25.69K
- Yesterday Close: $0.77
- Yesterday High: $0.788249
- Yesterday Low: $0.7555
- Yesterday Volume: 109.72K
- Last Min Volume: 1
- Last Min High: $0.794
- Last Min Low: $0.794
- Last Min VWAP: $0.794
Company Profile
- Name: Akari Therapeutics plc ADR (0.01 USD)
- Website: https://www.akaritx.com
- Listed Date: 2012-12-07
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001541157
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $25.73M
- Round Lot: 100
- Outstanding Shares: 32.61M
- Asset Type: ADRC
RECENT FILINGS FOR AKTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-29 | S-1 | View |
| 2025-08-29 | 8-K | View |
| 2025-08-29 | 4 | View |
| 2025-08-21 | 8-K | View |
| 2025-08-19 | 8-K | View |
| 2025-08-13 | 10-Q | View |
| 2025-07-31 | EFFECT | View |
| 2025-07-30 | CORRESP | View |
| 2025-07-30 | UPLOAD | View |
| 2025-07-29 | S-8 | View |
| 2025-07-29 | S-3 | View |
| 2025-07-01 | 8-K | View |
| 2025-06-25 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-06 | ARS | View |
| 2025-06-06 | DEF 14A | View |
| 2025-05-23 | PRE 14A | View |
Latest News on AKTX